Editorial comment--what can models teach us about stroke treatment? Sorting out the missing bits.
Matchar
David B
DB
D003362:Cost-Benefit Analysis; D006801:Humans; D018803:Models, Economic; D008962:Models, Theoretical; D020521:Stroke / Q000188:drug therapy* / Q000191:economics*; D015912:Thrombolytic Therapy / Q000191:economics*; D010959:Tissue Plasminogen Activator / Q000191:economics / Q000627:therapeutic use; D006113:United Kingdom
D010959:Tissue Plasminogen Activator